Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11883490 Induction of IL-12 using immunotherapy

Patent 11883490 was granted and assigned to Mirror Biologics, Inc. on January, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Mirror Biologics, Inc.
Mirror Biologics, Inc.
0
Date Filed
May 20, 2021
0
Date of Patent
January 30, 2024
0
Patent Applicant
Mirror Biologics, Inc.
Mirror Biologics, Inc.
0
Patent Application Number
17326009
0
Patent Citations
‌
US Patent 7402431 T-cell therapy formulation
0
‌
US Patent 7435592 Compositions for allogeneic cell therapy
0
‌
US Patent 7678572 Methods for preparing T-cells for cell therapy
0
‌
US Patent 8354276 T-cell compositions that elicit type I cytokine response
0
‌
US Patent 8679841 Allogeneic cell compositions with cross-linked CD3/CD28
0
‌
US Patent 8778678 Composition of activated CD4 cells
0
‌
US Patent 9233156 Induction of IL-12 using immunotherapy
0
‌
US Patent 9272001 Ablative immunotherapy
0
‌
US Patent 6867041 Simultaneous stimulation and concentration of cells
0
‌
US Patent 6887466 Methods for selectively stimulating proliferation of T cells
0
•••
Patent Inventor Names
Michael Har-Noy
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11883490
0
Patent Primary Examiner
‌
Prema M Mertz
0
CPC Code
‌
A61K 38/208
0
‌
A61K 2039/55522
0
‌
A61K 2039/5158
0
‌
A61K 39/39
0

Find more entities like US Patent 11883490 Induction of IL-12 using immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo